Today's Date: October 4, 2023
Consumers Energy Continues Clean Energy Transition with Plans for Solar Project at Former Coal Plant Location   •   Avangrid Schedules Third Quarter 2023 Earnings Release and Conference Call   •   Cartamundi and Warner Bros. Discovery Global Consumer Products Unveil the DC “Selfie Moments” Limited-Edition Hybrid   •   Grupo EULEN announces Angeles Campoy as the New Chief Executive Officer for USA   •   CAMS Wins Ragan CSR, ESG and Diversity Awards   •   NAREB's 60-CITY, BLACK WEALTH TOUR BEGINS IN HOUSTON WITH A COMMUNITY WEALTH BUILDING DAY   •   Dr. Toba N. Niazi Appointed Chief of the Section of Neurosurgery and Co-Director of Nicklaus Children's Brain Institute   •   Global Clean Energy Reports Largest Camelina Acreage Worldwide   •   Qwoted Launches Free Networking Tools for PR Industry   •   Six wheelchair tennis players nominated to Santiago 2023 Canadian Parapan Am Team   •   Indie Beauty and Wellness Brand LĀ SOL Collective Expands Product Line with HYDRATE Body Oil   •   FINRA Foundation Awards 2023 Ketchum Prize to Long-Time Financial Fraud Fighter Doug Shadel   •   MERGE Acquires Zee Jay Digital to Orchestrate the Content Supply Chain for Superior CX   •   Illume Fertility Founder and Medical Director, Dr. Mark Leondires, Co-Authors the First All-Inclusive Guide to Donor Conception   •   Get a Free Google Pixel 8 and Unleash its Full 5G Potential Only at T-Mobile, America’s 5G Leader   •   Statement - Ministers Anandasangaree, Vandal, Hajdu, and Ien issue a statement of support on Sisters in Spirit Day and the Natio   •   HTeaO Kicks Off 'Round Up with the Ryan Palmer Foundation'   •   ACE Cash Express Supports Homes For Our Troops to Help Veterans Rebuild Their Lives   •   Vancouver International Airport Selects LAT Multilingual to Engage with Chinese Travellers   •   Patrick and Brittany Mahomes’ 15 and the Mahomies Foundation Establishes National Partnership With Boys & Girls Clubs
Bookmark and Share

HighField Biopharmaceuticals’ HF1K16, a New Immuno-Oncology Drug, Shows Promise in Patients with Refractory Glioblastoma

HANGZHOU, China , May 31 /Businesswire/ - HighField Biopharmaceuticals (HighField Bio), a clinical stage immuno-oncology company using immunoliposomes to treat cancer, announced today the publication of an abstract including preliminary data from a Phase 1a clinical trial of HF1K16 in refractory metastatic cancer patients. It was published online at the American Society of Clinical Oncology (ASCO) Annual Meeting. HF1K16 is a drug encapsulated immune modulating liposome containing all-trans retinoic acid. The ASCO meeting is June 2 – 6, 2023, at the McCormick Place, Chicago, IL.

The HighField Bio abstract is titled “Modulating MDSCs by HF1K16: a monotherapy Phase 1a study examining safety and preliminary efficacy in refractory and metastatic cancer patients.”

“We are excited about the preliminary data,” said Yuhong Xu, CEO of HighField Bio. “The data show HF1K16 is well tolerated and patients have experienced significant progression-free survival.” The abstract also reports that of the 11 patients treated, three who suffer from recurrent and refractory glioma continued to experience progression-free survival. One patient has been on treatment for 348 days. The other two are 94 days and 52 days with progression-free survival from the start of treatment.

Dr. Xu noted, “Four patients reached stable disease diagnosis based on RECIST 1.1 criteria. One patient experienced a reduction in size of the main brain lesion from 70mm to 23.7mm.”

HF1K16 is a unique liposome construct of ATRA, a small molecule metabolite of vitamin A, administered by infusion, and travels through the blood stream and infiltrates the tumor microenvironment. ATRA is released and initiates the maturation of Myeloid-Derived Suppressor Cells (MDSCs).

MDSCs are immature myeloid cells which have not differentiated. ATRA promotes the maturation and differentiation of MDSCs into functional cells, such as dendritic cells, which then summon T cells to attack the cancer.

The preliminary data reported at ASCO is from an ongoing Phase 1a trial in China with patients suffering from a variety of refractory metastatic cancers. Based on the positive findings related to glioma, HighField Bio expects to begin a Phase 1b/2 trial in China for patients with refractory glioma in the next few weeks.

About HighField Biopharmaceuticals

HighField Bio is a clinical stage immuno-oncology company focused on novel applications of liposome constructs to disrupt existing immuno-oncology technologies. The company has a research and development center and a GMP-compliant production facility. HighField Bio’s lead clinical development program is HF1K16, a drug encapsulated immune modulating liposome containing all-trans retinoic acid targeting myeloid-derived suppressor cells for treatment of solid tumors. For more information visit

STORY TAGS: Conference, Product/Service, Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, China, United States, North America, Asia Pacific, Illinois,


White House Live Stream
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Sounds Make the News ®
Atlanta - WAOK-Urban
Berkley / San Francisco - KPFA-Progressive
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
Washington - WOL-Urban

Listen to United Natiosns News